Company: Lexaria Bioscience Corp.
Chairman, CEO and President: Chris Bunka
Markets: CSE: LXX, OTCQX: LXRP
“Lexaria owns one of the largest patent portfolios within the medicinal cannabis space. The stock is currently undervalued but with the number of pending patents, I believe it won’t remain undervalued for much longer.”
Greg Beckett, Senior Analyst and Chartered Investment Manager for the Richmond Club
Partnerships, studies and other achievements
Lexaria developed DehydraTECH™ in partnership with U.S.-based Altria Group (Altria), one of the world’s largest producers and marketers of tobacco and cannabis products. DehydraTECH™ is a non-smokable nicotine alternative and drug delivery method that is disrupting the biotech sector. It makes nicotine, cannabis and ibuprofen easier to ingest, delivering relief faster and at a lower dosage. Lexaria will receive royalties from Altria, giving it a competitive edge in the pharmaceutical market.
“Our technology has the ability to change the world,” says Chris Bunka, Lexaria’s Chairman and CEO. “We can save lives and improve lives through faster and healthier means of ingesting these drugs
In 2018, Lexaria completed the world’s first human clinical study on the use of cannabidiol (CBD), which showed that the company’s formulations help lower blood pressure in humans. “Formulations from our competitors have no impact on blood pressure,” says Bunka. “We also delivered over 300 per cent more CBD in 30 minutes with our formulation when compared with the generic industry version. We’ve shown that the technology works and that it has a positive effect on human health.”
“Lexaria’s DehydraTECH™ is designed to save lives,” says Greg Beckett, Richmond Club Senior Analyst and Chartered Investment Manager, who picks stocks for the Richmond Club Index. Over the last decade and a half his picks have averaged a return of approximately 20% per year. “It’s no surprise the company owns one of the largest patent portfolios in the medicinal cannabis space. The stock is currently undervalued but with the number of pending patents, I believe it won’t be undervalued for much longer.”
Beckett believes now is the time to invest in Lexaria for the following reasons:
- Partnership with Altria Group – Partnering with one of the largest tobacco companies in the world means Lexaria has access to the resources it needs to develop and distribute its unique product, even as it earns royalties.
- Lexaria owns one of the largest patent portfolios in the medical cannabis sector – With 15 granted patents and 60 more patents pending, the company is distinguishing itself from its peers in the space.
- Lexaria is developing a global footprint – The company has operations in Canada and the USA and discussions are underway for expansion into Mexico and Europe.
- Lexaria is trading at a 52-week low, but revenue growth is on the horizon – The company expects to grow from one single paying customer to as many as seven over the coming year, which would lead to a dramatic change in its revenue streams for 2019 and 2020.